Have a feature idea you'd love to see implemented?
Let us know!
AUPH Aurinia Pharmaceuticals Inc
Price (delayed)
$8.77
Market cap
$1.26B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.14
Enterprise value
$1.31B
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The
Highlights
Aurinia Pharmaceuticals's EPS has surged by 74% YoY and by 58% QoQ
The net income has soared by 71% YoY and by 55% from the previous quarter
Aurinia Pharmaceuticals's debt has decreased by 6% YoY but it has increased by 2.2% QoQ
The quick ratio rose by 6% since the previous quarter but it has declined by 3.7% year-on-year
The gross margin has declined by 7% year-on-year
Key stats
What are the main financial stats of AUPH
Market
Valuations
Earnings
Shares outstanding
143.18M
Market cap
$1.26B
Enterprise value
$1.31B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.23
Price to sales (P/S)
5.69
EV/EBIT
N/A
EV/EBITDA
297.58
EV/Sales
5.93
Revenue
$220.36M
EBIT
-$15.14M
EBITDA
$4.39M
Free cash flow
$28.3M
Per share
Balance sheet
Liquidity
EPS
-$0.14
Free cash flow per share
$0.2
Book value per share
$2.71
Revenue per share
$1.54
TBVPS
$3.81
Total assets
$549.36M
Total liabilities
$161.36M
Debt
$87.85M
Equity
$388M
Working capital
$361.85M
Debt to equity
0.23
Current ratio
5.6
Quick ratio
4.9
Net debt/EBITDA
11.55
Margins
Efficiency
Dividend
EBITDA margin
2%
Gross margin
87.3%
Net margin
-10.2%
Operating margin
-14.8%
Return on assets
-4.2%
Return on equity
-6.1%
Return on invested capital
-3%
Return on capital employed
-3.2%
Return on sales
-6.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AUPH stock price
How has the Aurinia Pharmaceuticals stock price performed over time
Intraday
6.43%
1 week
5.28%
1 month
22.32%
1 year
0.34%
YTD
-2.45%
QTD
19.65%
Financial performance
How have Aurinia Pharmaceuticals's revenue and profit performed over time
Revenue
$220.36M
Gross profit
$192.27M
Operating income
-$32.69M
Net income
-$22.55M
Gross margin
87.3%
Net margin
-10.2%
Aurinia Pharmaceuticals's net margin has surged by 79% YoY and by 58% QoQ
The operating margin has soared by 74% YoY and by 49% from the previous quarter
The net income has soared by 71% YoY and by 55% from the previous quarter
The operating income has soared by 64% year-on-year and by 46% since the previous quarter
Growth
What is Aurinia Pharmaceuticals's growth rate over time
Valuation
What is Aurinia Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.23
P/S
5.69
EV/EBIT
N/A
EV/EBITDA
297.58
EV/Sales
5.93
Aurinia Pharmaceuticals's EPS has surged by 74% YoY and by 58% QoQ
The price to book (P/B) is 25% lower than the 5-year quarterly average of 4.3 but 24% higher than the last 4 quarters average of 2.6
AUPH's equity is up by 6% since the previous quarter
The stock's P/S is 100% less than its 5-year quarterly average of 1625.2 but 14% more than its last 4 quarters average of 5.0
The revenue has increased by 39% YoY and by 6% from the previous quarter
Efficiency
How efficient is Aurinia Pharmaceuticals business performance
Aurinia Pharmaceuticals's return on sales has surged by 85% YoY and by 67% QoQ
AUPH's ROIC has soared by 83% year-on-year and by 65% since the previous quarter
The company's return on assets has surged by 72% YoY and by 55% QoQ
The ROE has soared by 69% YoY and by 55% from the previous quarter
Dividends
What is AUPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AUPH.
Financial health
How did Aurinia Pharmaceuticals financials performed over time
The quick ratio rose by 6% since the previous quarter but it has declined by 3.7% year-on-year
Aurinia Pharmaceuticals's total assets has increased by 4.9% QoQ
Aurinia Pharmaceuticals's debt is 77% lower than its equity
Aurinia Pharmaceuticals's debt has decreased by 6% YoY but it has increased by 2.2% QoQ
AUPH's equity is up by 6% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.